TransMedics Group (NASDAQ:TMDX) had its price target raised by analysts at Morgan Stanley from $123.00 to $135.00. They now have an "equal weight" rating on the stock.
TransMedics to Participate in the Piper Sandler 37th Annual Healthcare Conference
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
TransMedics Group (NASDAQ:TMDX) had its price target lowered by analysts at Piper Sandler from $145.00 to $140.00. They now have an "overweight" rating on the stock.
TransMedics Group (NASDAQ:TMDX) had its "buy" rating reaffirmed by analysts at Canaccord Genuity Group Inc..